#PharmaStrategy #MedicoMarketing #MedicalAffairs #PharmaLeadership #GLP1 #DiabetesCare #ObesityManagement #HealthcareInnovation #PharmaIndia #EmergingMarkets #MarketAccess #PharmaCommercial #HealthcareLeadership #IndianPharmaLeaders
This [trial] led to the FDAs approval in June 2021 of a once-weekly injectable GLP-1 under the brand name Wegovy [for weight management in individuals with overweight and obesity who have at least one weight-related condition], Dr
If you have a Limited Purpose FSA, only dental and vision services qualify
Alternative options include SGLT2 inhibitors (which offer cardiovascular and renal benefits), switching from a DPP-4 inhibitor to a GLP-1 receptor agonist, adding insulin therapy, or considering other medication classes based on your individual circumstances
Many consistent alterations in the microbiome lead toward a causative or contributory role, and early interventions of microbiota could influence the progression of the disease and the severity of its symptoms
If you meet the eligibility criteria, well prescribe a clinically approved treatment plan and practical tips tailored to your specific needs